Cancer BiologyMolecular Cancer TherapeuticsPeer-reviewed
TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy
Marcus Gerlach, Saskia Schmitt, Philipp Cyprys…·Jonas Helma
TUB-010 is an anti-CD30 ADC using Tub-tag conjugation technology that reduces toxicity and improves therapeutic window compared to Adcetris.